OverviewSuggest Edit

Cerecor is a clinical-stage biopharmaceutical company, which develops drugs to treat patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.

TypePublic
Founded2011
HQRockville, MD, US
Websitecerecor.com

Latest Updates

Employees (est.) (Dec 2019)18(-71%)
Revenue (FY, 2020)$6.7 M
Share Price (Jun 2021)$2.9(+7%)
Cybersecurity ratingBMore

Key People/Management at Cerecor

Sol J. Barer

Sol J. Barer

Chairman of the Board
Gilla Kaplan

Gilla Kaplan

Director
James A. Harrell

James A. Harrell

Chief Commercial Officer
Garry Neil

Garry Neil

Chief Scientific Officer
Younok Dumortier Shin

Younok Dumortier Shin

Chief Technology Officer
Schond L. Greenway

Schond L. Greenway

Chief Financial Officer
Show more

Cerecor Office Locations

Cerecor has offices in Rockville and Chesterbrook
Rockville, MD, US (HQ)
540 Gaither Rd #400
Chesterbrook, PA, US
1500 Liberty Ridge Dr #321
Show all (2)

Cerecor Financials and Metrics

Cerecor Revenue

Cerecor's revenue was reported to be $6.7 m in FY, 2020
USD

Revenue (Q1, 2021)

473.0k

Gross profit (Q1, 2021)

396.0k

Gross profit margin (Q1, 2021), %

83.7%

Net income (Q1, 2021)

(30.7m)

EBIT (Q1, 2021)

(30.6m)

Market capitalization (4-Jun-2021)

280.5m

Closing stock price (4-Jun-2021)

2.9

Cash (31-Mar-2021)

38.3m
Cerecor's current market capitalization is $280.5 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

27.8m18.3m6.8m6.7m

Cost of goods sold

635.6k7.5m566.5k300.2k

Gross profit

27.2m10.8m6.2m6.4m

Gross profit Margin, %

98%59%92%96%
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

25.0m4.5m4.8m4.1m5.4m4.4m5.6m2.8m1.3m473.0k

Cost of goods sold

863.6k1.4m3.1m1.9m141.8k1.4m66.6k77.6k77.0k

Gross profit

3.6m3.4m963.5k3.5m4.3m4.2m2.7m1.3m396.0k

Gross profit Margin, %

81%70%24%64%97%74%98%94%84%
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

21.2m5.1m2.5m10.6m3.6m18.9m

Accounts Receivable

3.3m3.2m1.0m2.2m

Prepaid Expenses

703.2k1.5m707.0k2.7m

Inventories

401.6k391.3k382.2k1.1m21.3k3.1k
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

3.3m16.6m11.9m8.8m3.0m5.5m24.0m2.5m2.2m6.8m16.1m9.4m5.3m5.7m45.4m38.3m

Accounts Receivable

2.8m3.3m3.0m2.7m2.9m5.0m2.2m2.0m3.1m

Prepaid Expenses

105.1k231.5k542.0k210.0k249.6k402.3k341.0k774.3k954.5k1.3m1.2m865.1k1.7m777.4k823.9k2.5m

Inventories

3.4m1.5m1.1m1.0m617.6k402.3k16.3k12.2k
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(10.5m)(16.5m)11.9m(40.1m)(16.1m)(63.5m)

Depreciation and Amortization

23.5k26.9k425.5k4.6m3.9m1.8m

Inventories

2.7m(202.6k)(311.2k)532.9k18.2k

Accounts Payable

(268.7k)332.1k96.1k82.5k1.0m98.5k
USDQ3, 2015

Debt/Equity

-0.2 x

Debt/Assets

1.2 x

Financial Leverage

-0.2 x
Show all financial metrics

Cerecor Acquisitions / Subsidiaries

Company NameDateDeal Size
Ichorion TherapeuticsSeptember 28, 2018$27 m

Cerecor Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Cerecor Online and Social Media Presence

Embed Graph

Cerecor News and Updates

Cerecor Enters Into $35 Million Debt Financing Agreement With Horizon Technology Finance

ROCKVILLE, Md. and CHESTERBROOK, Pa., June 07, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced that it has entered into a debt financi…

Thinking about buying stock in LightPath Technologies, Minerva Neurosciences, Cerecor, Eloxx Pharmaceuticals, or Soleno Therapeutics?

NEW YORK, May 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LPTH, NERV, CERC, ELOX, and SLNO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Cerecor to Participate in Upcoming Investor Conferences

ROCKVILLE, Md. and CHESTERBROOK, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced that members of its senior management te…

Cerecor Doses First Patient in a Phase 1b Proof-of-Concept Clinical Trial of CERC-007 for the Treatment of Adult Onset Still’s Disease

ROCKVILLE, Md. and CHESTERBROOK, Pa., May 05, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that it has dosed its first patient in a Pha…

Cerecor Announces New Worldwide License Agreement with Kyowa Kirin for Anti-LIGHT Antibody CERC-002

ROCKVILLE, Md., March 29, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced that its wholly-owned subsidiary, Aevi Genomic Medicine, LLC…

Thinking about buying stock in Cerecor, Surface Oncology, SINTX Technologies, Clearpoint Neuro, or Senseonics Holdings?

NEW YORK, March 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CERC, SURF, SINT, CLPT, and SENS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Show more

Cerecor Blogs

Cerecor Reports First Quarter 2021 Financial Results and Provides Business Updates

Announced CERC-002 received Fast Track Designation from the U.S. Food and Drug Administration, following positive Phase 2 clinical trial for the treatment of patients hospitalized with COVID-19 ARDS Secured exclusive, world-wide rights to develop, manufacture and commercialize CERC-002 for all in…

Cerecor Reports 2020 Financial Results and Provides Business Updates

  • Announced CERC-002 significantly reduced respiratory failure and mortality in Phase 2 clinical trial in patients hospitalized with COVID-19 ARDS   • Improved financial position with $18.9M of cash on hand as of December 31, 2020 and $37.6M of net proceeds raised in January 2021   • Poised …

Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for the Treatment of Still’s Disease

ROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that its Investigational New Drug Applicati…

Cerecor to Present at Upcoming Investor Conferences

ROCKVILLE, Md. and CHESTERBROOK, Pa., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that Michael F. Cola, President and Chief …

Cerecor Resumes Phase 1b Clinical Trial of CERC-002 for the Treatment of Severe Pediatric Onset Crohn’s Disease

ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ : CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced it has resumed the Phase 1b clinical study…

Cerecor Announces Peer-Reviewed Publication Highlighting the Role of the Inflammatory Cytokine, LIGHT, in COVID-19 ARDS

The data strongly support Cerecor’s ongoing clinical study of CERC-002 as a novel potential treatment for COVID-19-related ARDS ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ : CERC), a biopharmaceutical company focused on becoming a leader in develop…
Show more

Cerecor Frequently Asked Questions

  • When was Cerecor founded?

    Cerecor was founded in 2011.

  • Who are Cerecor key executives?

    Cerecor's key executives are Sol J. Barer, Gilla Kaplan and James A. Harrell.

  • How many employees does Cerecor have?

    Cerecor has 18 employees.

  • What is Cerecor revenue?

    Latest Cerecor annual revenue is $6.7 m.

  • What is Cerecor revenue per employee?

    Latest Cerecor revenue per employee is $372.1 k.

  • Who are Cerecor competitors?

    Competitors of Cerecor include Macleods Pharmaceuticals, Apotex and Octapharma.

  • Where is Cerecor headquarters?

    Cerecor headquarters is located at 540 Gaither Rd #400, Rockville.

  • Where are Cerecor offices?

    Cerecor has offices in Rockville and Chesterbrook.

  • How many offices does Cerecor have?

    Cerecor has 2 offices.